Nakagawa, Noriharu
Ishiyama, Ken http://orcid.org/0000-0002-6189-0620
Usuki, Kensuke
Takada, Satoru
Tomikawa, Tatsuki
Handa, Hiroshi
Katsuoka, Yuna
Hirano, Daiki
Sezaki, Nobuo
Sumi, Masahiko
Fujisawa, Shin
Taniguchi, Yasuhiro
Mugitani, Atsuko
Yoshimura, Takuro
Ohtsuka, Eiichi
Takase, Ken
Suehiro, Youko
Ota, Shuichi
Kajiguchi, Tomohiro
Maeda, Tomoya
Yamamoto, Masahide
Ohtake, Shigeki
Katsumi, Akira
Kiyoi, Hitoshi
Matsumura, Itaru
Miyazaki, Yasushi
Funding for this research was provided by:
Japan Adult Leukemia Study Group
Article History
Received: 12 May 2023
Accepted: 26 October 2023
First Online: 8 November 2023
Declarations
:
: This study was approved as an accompanying study of JALSG-CS-11 by the committee for the Japan Adult Leukemia Study Group (JALSG) and by the ethical committee of Kanazawa University (No. 2018–227) and all participating institutions. Informed consent was obtained from all the participants.
: Kensuke Usuki has received research funding from Astellas-Amgen-Biopharma, Otsuka, Apellis, SymBio, Takeda, Nippon Shinyaku, Novartis, AbbVie, Janssen, Bristol-Myers Squibb, Ono, Chugai, Daiichi Sankyo, MSD, Astellas, Alexion, Kyowa-Kirin, Gilead, Pfizer, Incyte, SymBio, Celgene, Sumitomo-Dainippon, Mundi, Yakult, and Eisai, and has served on speaker bureaus for Novartis, Astellas, Alexion, Eisai, MSD, Otsuka, Ono, Kyowa-Kirin, Celgene, Daiichi Sankyo, Takeda, Nippon-Shinyaku, PharmaEssentia, Bristol-Myers Squibb, Yakult, Sanofi, Pfizer, AbbVie, and Chugai, and has served on consulting bureaus for Alexion, SymBio, Nippon Shinyaku, Otsuka, Chugai, Sanofi, Takeda, Kyowa-Kirin, Astellas, SOBI, and Alnylam Japan. Shin Fujisawa received honoraria from Bristol-Myers-Squibb, Astellas, Nippon Shinyaku, Otsuka, Pfizer, Novartis, MSD, Sanofi, Janssen, SymBio, Kyowa Hakko Kirin, AstraZeneca, CSL Behring, Meiji Seika Pharma, AbbVie, Takeda, and Chugai, and received research funding from Shionogi, Kyowa Hakko Kirin, Chugai, Otsuka, Asahi-Kasei, and Daiichi Sankyo. Tomoya Maeda received honoraria from Amgen, Nippon Becton Dickinson Company, Nippon Shinyaku, Novartis, Otsuka, Pfizer, and TOPPAN and received research funding from Chugai, Eisai, and Sumitomo Pharma. Masahide Yamamoto received honoraria from Bristol-Myers Squibb, Chugai, Eisai, Kyowa-Kirin, Nippon Shinyaku, Novartis, Ono, Otsuka, Pfizer, Takeda, Sanofi, Janssen, AbbVie, SymBio, and Meiji Seika. Hitoshi Kiyoi received research funding from FUJIFILM, Kyowa-Kirin, Bristol-Myers Squibb, Otsuka, Perseus Proteomics, Daiichi Sankyo, AbbVie, CURED, Astellas, Chugai, Zenyaku Kogyo, Nippon Shinyaku, Eisai, Takeda, Sumitomo Pharma, Sanofi, and Honoraria from AbbVie, Chugai, Astellas Pharma, and Novartis. Itaru Matsumura has received research funding from Kyowa-Kirin, Chugai, Novartis, Astellas, AbbVie, Pfizer, Takeda, Alexion, Otsuka, Janssen, Sumitomo-Dainippon, Shionogi, Asahi-Kasei, Eisai, TAIHO, Nippon Shinyaku, Ono, Sanofi, and Mitsubashi Tanabe and has received honoraria from Novartis, Bristol-Myers Squibb, Pfizer, Daiichi Sankyo, Otsuka, Astellas, Janssen, AbbVie, Takeda, Ono, and SymBio. Yasushi Miyazaki received honoraria from Nippon Shinyaku, Bristol-Myers Squib, Novartis, Sumitomo Pharma, Kyowa-Kirin, AbbVie, Daiichi-Sankyo, Takeda, Janssen Pharmaceutical, Astellas, Pfizer, Chugai, SymBio, and Otsuka Pharmaceutical, and research funding from Sumitomo-Dainippon.